CD8A and neoplasm: To date, preclinical studies of bintrafusp alfa have focused primarily on the activation of CD8+ T cells and NK cells in the tumor microenvironment (TME) of tumors derived from murine breast and colorectal cell lines, but its effectiveness on the poorly immunogenic microenvironment associated with SCC has not been shown.